Post hoc analysis demonstrates equivalent outcomes for subcutaneous infliximab with or without immunosuppressants in inflammatory bowel disease, indicating monotherapy is viable.
Despite some differences in pharmacokinetics and immunogenicity between CT-P13 SC received alone or in combination with immunosuppressants in patients with CD or UC, efficacy outcomes at week 54 or week 102 were generally comparable. The overall safety profile and incidence of systemic injection reactions were also comparable between monotherapy and combination therapy.
No takes yet. Share an insight, caveat, or question.
Schreiber et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: